Search results for: Precision Medicine

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

1 February 2017

…approach for assessing regenerative medicines, but rather to test whether regenerative medicines could fit into the existing pathway developed for conventional medicines. The authors suggest a more interesting question would…

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

17 March 2020

Adrian Towse presented evidence that transparency of process reduced corruption and improved competition. Evidence was, however, against price transparency for on-patent medicines. It will reduce access in low income countries….

Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?

12 January 2014

…how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems. This OHE Occasional Paper by Adrian Towse discusses…

2022 Innovation Policy Prize

…medicines to approve for reimbursement, and at what price. As higher–cost medicines put increasing pressure on public health care budgets [3], the need to identify ‘fair’ prices for medicines has never been…

Canberra Hypothesis: the Economics of the Prescription Medicine Market

1 July 1975

The burden of this paper was that it was a fundamental misconception to believe that price competition was lacking in the prescription medicine market, at least in the context of…

Question of Balance: the Benefits and Risks of Pharmaceutical Innovation

1 May 1980

…in which damages have been awarded because a medicine taken during pregnancy was… Since this monograph was completed, two new stories concerning the safety of medicines have been featured prominently…

What do Pharmaceuticals Really Cost in the Long Run?

6 October 2017

…OHE’s collaboration with Darius Lakdawalla (University of Southern California), Joanna MacEwan (Precision Health Economics), Robert Dubois (National Pharmaceutical Council) and Kimberly Westrich (National Pharmaceutical Council).   The policy debate over…

The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’

3 December 2020

Bernarda Zamora presented at the virtual event entitled ‘Value of Diagnostic Information in Heart Failure’, which was organised by Roche Diagnostics. The panel, composed of six experts representing a range…

Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.

12 April 2016

…topic of the economics of the market for medicines. The first half of the lecture included an overview of the global challenges facing medicines manufacturers, discussion of the ‘supply side’…